{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'requirements, and a detailed written explanation of the reasons for the termination/halt should be', 'given.', '16.2.', 'Ethical Conduct of the Study', 'The study will be performed in accordance with ethical principles that have their origin in the', 'Declaration of Helsinki and are consistent with ICH/GCP guidelines, applicable regulatory', \"requirements and the Sponsor's policy on Bioethics.\", '16.3.', 'Written Informed Consent', 'The Investigator will ensure that the subject (parents/guardians/caregivers, as needed) is given', 'full and adequate oral and written information about the nature, purpose, possible risk and', 'benefit of the study. Subjects (parents/guardians/caregivers, as needed) must also be notified', 'that they are free to discontinue from the study at any time. The subject', '(parents/guardians/caregivers, as needed) should be given the opportunity to ask questions and', 'allowed time to consider the information provided.', 'The Investigator is responsible for obtaining informed consent from each subject/legally', 'acceptable representative (LAR) participating in the study. An ICF will contain all US (federal', 'and state specific) requirements, all ICH-required elements, and Health Insurance Portability and', 'Accountability Act information in a language that is understandable to the subject. The process', 'of obtaining informed consent will be in compliance with all US federal regulations, ICH', 'requirements, and local laws. All pertinent aspects of the study must be explained to the', \"subject/LAR before he or she signs the ICF. The subject's signed and dated informed\", 'consent/assent must be obtained before conducting any study procedures.', 'Informed consent/assent must be obtained from the subject/LAR before any activity or treatment', 'is undertaken which is not part of routine care. This includes, but is not limited to, the', 'performance of diagnostic or therapeutic screening procedures and the administration of the first', 'dose of the study medication. Each subject (parents/guardians/caregivers, as needed) must be', 'informed that participation in the study is voluntary, that he/she may withdraw from the study at', 'any time, and that withdrawal of consent will not affect his/her subsequent medical treatment or', 'relationship with the treating physician.', 'This informed consent should be given by means of a standard written statement, written in', 'nontechnical language. The subject/LAR should understand the statement before signing and', 'dating it and will be given a copy of the signed document.', 'Each subject/LAR must sign an approved ICF(s) before study participation. The form(s) must', 'be', 'signed and dated by the appropriate parties. The Investigator(s) must maintain the original,', 'signed ICF. A copy of the signed ICF must be given to the subject.', \"The subject (parents/guardians/caregivers, as needed or the subject's LAR should be informed in\", \"a timely manner if new information becomes available that may be relevant to the subject's\", 'willingness to continue participation in the study. The communication of this information should', 'be documented. If required, informed consent should be obtained using an amended ICF(s) for', \"the subject's continuation in the study.\", 'Glenmark', 'CONFIDENTIAL', 'Page 68 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '16.4.', 'Approval of the Protocol and Amendments', 'Subjects will not be admitted to the study before approval of the study protocol and other', 'relevant study documents by the IRB/IEC and Regulatory Authority.', 'Any change or addition to this protocol requires a written protocol amendment that must be', 'approved by the Sponsor, Principal Investigator and IRB/IEC before implementation.', 'Amendments significantly affecting the safety of subjects, the scope of the investigation or the', 'scientific quality of the study will require additional approval by the IRB/IEC and the Regulatory', 'Authority.', 'These requirements for approval will in no way prevent any immediate action from being taken', 'by the Principal Investigator in the interests of preserving the safety of the subjects included in', 'the study. If an immediate change to the protocol is considered necessary by the Principal', 'Investigator and is implemented for safety reasons the IRB/IEC will be informed within 7', 'working days. Changes affecting only administrative aspects of the study will not require formal', 'protocol amendments or IRB/IEC approval but the IRB/IEC will be kept informed of such', 'administrative changes.', 'Protocol amendments that affect only administrative aspects of the study may not require', 'submission to Health or Regulatory Authority or the IRB/IEC, but the Health or Regulatory', 'Authority and IRB/IEC should be kept informed of such changes as required by local', 'regulations. In these cases, the Investigator or Sponsor (or designee), may be required to send a', 'letter to the IRB/IEC and the Regulatory Authorities notifying them of such changes.', '16.5.', 'Protocol Deviation', 'The Investigator is responsible for the conduct of the study in accordance with the study', 'protocol. It is the responsibility of the site/Investigator to use continuous vigilance to identify', 'and report any deviations from the protocol. Any deviation from the protocol will be recorded as', 'a protocol deviation. Protocol deviations are defined as \"major\\' if they have significant influence', 'on efficacy - these are the criteria for subjects being excluded from PPS. Major protocol', 'deviations will be defined in the SAP and by clinical review prior to unblinding.', '17.', 'DATA HANDLING AND RECORDKEEPING', '17.1.', 'Data Collection', 'As part of the responsibilities assumed by participating in the study, the Investigator agrees to', 'maintain adequate and accurate case histories for the subjects treated under this protocol. Case', 'histories include CRFs and supporting data including, but not limited to, signed and dated', \"informed consent forms, progress notes, hospital charts, nurse's notes, diary cards, laboratory\", 'reports, ECG strips, etc.', 'Subject demographics will be collected, as available, for all subjects who provide written', 'informed consent. For subjects who provide informed consent and were not assigned to', 'treatment/randomized into the study, the reason the subject was not assigned to', 'treatment/randomized, ie, did not meet one or more inclusion criteria, met one or more exclusion', 'criteria, or other (eg, lost to follow-up, consent withdrawn), will also be collected.', 'Glenmark', 'CONFIDENTIAL', 'Page 69 of 90']\n\n###\n\n", "completion": "END"}